Posts From June, 2017

Anti-PDGF inhibitor development continues despite negative results

Reviewed by Pravin U. Dugel, MD Despite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues. Two phase III clinical trials designed to investigate the superiority of combination therapy with PDGF inhibitor E10030 (Fovista, Ophthotech)… Read More »